ArticleAlcohol, clinical & experimental research2025
Investigating pharmacotherapies for alcohol use disorder using Drosophila melanogaster.
Article in Alcohol, clinical & experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigating pharmacotherapies for alcohol use disorder using Drosophila melanogaster.Alcohol, clinical & experimental research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDrosophila melanogaster provides a powerful whole-organism approach for the therapeutic discovery of treatments for many disorders due to the ability to perform high-throughput drug studies with detailed molecular and cellular mechanisms. While Drosophila has been critical for identifying novel molecular and neural circuit mechanisms underlying alcohol responses, few studies assess the use of Drosophila for the investigation and discovery of pharmacological targets of alcohol use disorder (AUD). Determining appropriate doses that impact alcohol consumption and memory for alcohol reward without affecting acute locomotor responses is key to identifying effective AUD medications such as naltrexone, acamprosate, and topiramate. This pipeline can then be used to test novel pharmacotherapies, including γ-secretase inhibitors (such as dibenzazepine and compound E) as potential treatments for AUD.
methodsTo validate Drosophila as an effective model for studying pharmacological therapies for AUD, we identified nondisruptive drug doses in flies using feeding and locomotive assays. Then, we assessed their impact on ethanol consumption and conditioned preference in cue-induced alcohol-seeking after 1 or 3 days of training.
resultsNaltrexone and acamprosate significantly reduced ethanol food preference and 3-day conditioned preference, while topiramate did not. γ-secretase inhibitors dibenzazepine and compound E significantly decreased conditioned preference after 3 days.
conclusionDrosophila is a valuable model organism for identifying and characterizing new AUD pharmacotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.